The prognostically important 1;19 chromosomal translocation can alter the EZA gene on chromosome 1 9~1 3 in childhood B-cell precursor acute lymphoblastic leukemia (ALL), leading to formation of a fusion gene (€24-PISXI) that encodes a hybrid transcription factor with oncogenic potential. It is not known whether this molecular alteration is a uniform consequence of the t(1; 19) or is restricted t o translocation events within specific immunologic subtypes of the disease. Therefore, we studied leukemic cells from 25 cases of B-cell precursor ALL, with or without evidence of cytoplasmic Ig p heavy chains (clg); 17 cases had the t(1;19) by cytogenetic analysis. Leukemic cell DNA samples were analyzed by Southern blotting t o detect alterations within the EZA genomic locus; a polymerase chain reaction assay was used t o identify expression of chimeric E2A-pbx7 transcripts in leukemic cell RNA; and immunoblotting with anti-Pbxl antibodies was used t o detect hybrid E2A-Pbxl proteins. Of 11 cases of clg+ ALL with the t(l;l9), 10 had EZA-pbx7 chimeric transcripts with identical junctions and a characteristic set of HROMOSOh4ALTRANSLOCATIONS appear to be
The prognostically important 1;19 chromosomal translocation can alter the EZA gene on chromosome 1 9~1 3 in childhood B-cell precursor acute lymphoblastic leukemia (ALL), leading to formation of a fusion gene (€24-PISXI) that encodes a hybrid transcription factor with oncogenic potential. It is not known whether this molecular alteration is a uniform consequence of the t(1; 19) or is restricted t o translocation events within specific immunologic subtypes of the disease. Therefore, we studied leukemic cells from 25 cases of B-cell precursor ALL, with or without evidence of cytoplasmic Ig p heavy chains (clg); 17 cases had the t(1;19) by cytogenetic analysis. Leukemic cell DNA samples were analyzed by Southern blotting t o detect alterations within the EZA genomic locus; a polymerase chain reaction assay was used t o identify expression of chimeric E2A-pbx7 transcripts in leukemic cell RNA; and immunoblotting with anti-Pbxl antibodies was used t o detect hybrid E2A-Pbxl proteins. Of 11 cases of clg+ ALL with the t(l;l9), 10 had EZA-pbx7 chimeric transcripts with identical junctions and a characteristic set of HROMOSOh4ALTRANSLOCATIONS appear to be C important events in the development of the human leukemias.' In acute lymphoblastic leukemia (ALL), more than 20 different nonrandom rearrangements have been identified.' One of the most frequent is the t( 1;19), which involves the long arm of chromosome 1 (at q23) and the short arm of chromosome 19 (at p13). This translocation is found in the leukemic cells of 6.5% of children with ALL, including about 25% of the cases with cytoplasmic Ig heavy chains (cIg) in the lymphoblasts and 1% of cIg-cases with markers of early B-cell progenitor^.^.^ Molecular analysis of cIg' cases with the t(1;19)(q23;p13) has demonstrated that the translocation breakpoint on chromosome 19 occurs within a single intron of the E2A gene, which encodes transcription factors containing a helix-loop-helix DNA binding motif and dimerization domain.'-"' E2A proteins were originally identified by their binding to the &2 DNA sequence motif contained in the Ig K light-chain enhancer.".'* Similarly, the breakpoint on chromosome lq23 interrupts a homeobox gene known as PBXl (formerly PRL).8*9 As a result, chimeric transcripts are formed that fuse coding sequences of the E24 gene in frame with PBXl sequences. Chimeric E2A-Pbxl proteins are produced that retain the activator domain of the E2A protein but substitute a homeobox domain of the Pbxl protein for the helix-loop-helix DNA-binding and dimerization domain of E2A.8-'0,'3 At least two chimeric E2A-pbxl transcripts are produced by alternative splicing in leukemic cells, resulting in a family of chimeric proteins that may function as aberrant transcription factors. When cDNAs encoding two of the hybrid E2A-Pbxl proteins were introduced into mouse NIH-3T3 fibroblasts, the resulting cells were tumorigenic in nude mice, indicating that these hybrid gene products might contribute to leukemic cell gr~wth.'~ Recent studies show that cIg' B-cell precursor ALL with the t(1;19) may respond poorly to treatment that is effective EZA-Pbxl hybrid proteins. Each of these cases had EZA gene rearrangements, including the one in which fusion transcripts were not detected. By contrast, none of the six cases of t(l;l9)-positive, clg-ALL had evidence of rearranged E2A genomic restriction fragments, detectable EZA-pbxl chimeric transcripts, or hybrid EZA-Pbxl proteins. Typical chimeric EZA-pbx7 transcripts and proteins were detected in one of eight clg' leukemias in which the t(1;19) was not identified by cytogenetic analysis, emphasizing the increased sensitivity of molecular analysis for detection of this abnormality. We conclude that the molecular breakpoints in cases of clg-B-cell precursor ALL with the t(1;19) differ from those in clg+ cases with this translocation. Leukemias that express hybrid oncoproteins such as EPA-Pbxl or Bcr-Ab1 have had a poor prognosis in most studies. Thus, molecular techniques t o detect fusion genes and their aberrant products should allow more timely and appropriate treatment of these aggressive subtypes of the disease. o 7992 by The American Society of Hematology.
against other subtypes of B-lineage l e~k e m i a .~.~ If most cIg' cases contain identical E2A-pbxl chimeric transcripts and proteins, then molecular detection of these aberrant products would afford an attractive diagnostic alternative to conventional cytogenetic studies, which are difficult to perform in human leukemic cells and may yield apparently identical results for rearrangements that have completely different molecular conseq~ences.'~~'~ In this report, we demonstrate identical hybrid E2A-pbxl transcripts and proteins in most cases of cIg' ALL with the t( 1;19), but could not detect such features in cytogenetically indistinguishable t( 1;19) cases that were cIg-. Thus, molec-ular approaches are definitive and efficient in detecting the clinically important subgroup of childhood leukemia patients with E2A-PBXl rearrangements in their malignant cells.
MATERIALS AND METHODS
Patients and lymphoblast samples. This study included 25 patients who were admitted to St Jude Children's Research Hospital or to institutions participating in the Pediatric Oncology Group. Leukemic cells were obtained at the time of diagnosis from bone marrow aspirates and cryopreserved (2 x 10' cells per milliliter of medium containing 10% fetal calf serum and 10% dimethylsulfoxide). There were 17 cases of B-cell precursor ALL with the t(1;19) (11 cIg+ and 6 cIg-), and eight cytogenetically characterized control cases that lacked the t(1;19) ( Table 1 ). Written informed consent was obtained from the patients (when appropriate) and their parents or guardians, and the protocols for therapeutic and biologic studies were reviewed and approved by the institutions' human investigations review boards.
Bone marrow samples were studied for both the karyotype and the immunophenotype of the leukemic clones. Standard indirect immunofluorescence assays with monoclonal antibodies to lymphoid-associated antigens were used to classify cells as B-cell precursor (CD19', CD22', CD10*, HLA-DR', CD7-, CD5-), with or without cIg expression. Leukemias with immunophenotypes of T cells (CD7t plus CD5+ or CD2') and mature B cells (surface Igt) were excluded from further study. Leukemic cell karyotypes were determined by previously reported technique^.'^." Our designation of B-cell precursor leukemias as cIg' and cIg-corresponds to the pre-B and early pre-B classifications used by the Pediatric Oncology Group. 6 Highmolecular-weight DNA was extracted from leukemic lymphoblasts, digested with restriction endonucleases, subjected to electrophoresis in 0.8% agarose gels, and transferred to nylon membranes as previously described.I8 Filters were hybridized under stringent conditions with a '*P-labeled E2A cDNA probe (pE47M), containing a 300-bp fragment that spans the translocation junction site." Several restriction enzymes, including EcoRI, BamHI, and HindIII, were used initially, but Bgl I1 and Xba I most often showed rearranged bands due to the translocation; hence, they were used in all further analyses of DNA.
Using cDNA sequences representing the chimeric E2A-pbxl and normal E2A transcripts," we prepared a series of oligonucleotides for amplification of the RNA sequences by the polymerase chain reaction (PCR). The oligonucleotides included E5 (5' TGCACAAC-CACGCGGCCCTC 3') and E 3 (5' CTTCTCCTCCTC-CGAGTGGT 3'), used as sense and antisense strand primers for normal E2A RNA, and P3 (5' CGCCACGCC'ITCCGCTAACA 3'), a pbxl antisense strand primer reverse complementary to chimeric RNA sequences 90 bp from the translocation junction. Oligonucleotide EP (5 ' CGACTCCTACAGTGTTITGAGTATCC 3'), which contained 13 bp on each side of the Ea-pbxl junction site, was used as a specific probe to detect products amplified from chimeric transcripts on Southern blots. Similarly, oligonucleotide E (5' CGACTCCTACAGTGGGCTAGGGCGAG 3') was used as a probe to detect products amplified from normal E2A transcripts.
Total RNA was extracted from leukemic cells by the single-step method of Chomczynski and Sacchi.I9 cDNA was synthesized from 1 pg of total RNA with M-MLV reverse transcriptase (200 U) in PCR buffer (Perkin-Elmer Cetus, Norwalk, CT) containing random hexamer primers (100 pmol), deoxynucleotide triphosphates Immunophenoryping and cytogenetic analysis.
Analysis of E2A gene rearrangements in blast cell DNA.
Detection of chimeric E2A-pbxl transcripts.
(1 mmol/L each), and RNasin (20 U) at 37°C for 1 hour (final reaction volume, 20 pL). The mixture was then denatured at 95°C for 5 minutes and cooled on ice. For amplification of the cDNA products, oligonucleotide primers were added at a final concentration of 0.5 pmol/L in a total volume of 100 pL. Taq polymerase (2.5 U; Perkin-Elmer Cetus) was then added and 40 cycles of amplification were performed in a DNA thermal cycler (Perkin-Elmer Cetus) with a stepwise program consisting of 95°C for 0.5 minutes, 62°C for 0.5 minutes, and 72°C for 0.5 minutes. The PCR products were separated by electrophoresis on 1.2% agarose gels, transferred to nylon membranes, and hybridized to either the E or EP radiolabeled oligonucleotide probes. RNAs from the 697 clg', B-cell precursor line [t(1;19)+], and the HL-60 myeloid cell line [t(1;19)-] were used as positive and negative controls, respectively.
To avoid false-positive results in sensitive PCR assays that could be due to contamination of reaction mixtures with small amounts of the E2A-pbxl template, we used disposable glass microcapillary pipettes for RNA templates and positive displacement pipettes with disposable tips and plungers for other components. As an additional precaution, tubes containing buffers and oligonucleotides were treated with UV radiation (254 nm) for 5 minutes before they were added to the cDNA templates for PCR assays.
To identify E2A-Pbxl proteins, leukemic cells were solubilized by boiling in sodium dodecyl sulfate (SDS)-containing Laemmli sample buffer at a concentration of 2 x 10' per milliliter. Aliquots of these samples equivalent to 4 x lo5 cells were resolved by electrophoresis in SDS-denatured polyacrylamide gels and transferred to nitrocellulose. Filters were incubated with 10 pg/mL affinity-purified anti-PBX Ig followed by alkaline phosphatase-conjugated goat antirabbit Ig, as previously described."
For detection of Ig p heavy chains, 2 x lo7 cells were solubilized in 1 mL of NP40 lysis buffer (0.05 mol/L Tris HC1, pH 7.4, 150 mmol/L NaC1, 0.5% NP40, and 0.5% sodium deoxycholate). Nuclei were pelleted and lysates were immunoprecipated with goat antibodies to human Ig p heavy chains, followed by protein A-sepharose. The samples were then resolved by electrophoresis under denaturing conditions in polyacrylamide gels containing SDS. After electrophoretic transfer of proteins to nitrocellulose, filters were incubated with goat antibodies specific for human Ig p chains, followed by '2SI-labeled protein A. 
Detection of EM-Pbxl and clgproteins.

RESULTS
Zmmunophenotypic and cytogenetic features related to the t(1;19
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E2A gene rearrangements. Using Southern blot analysis and an E2A cDNA probe, we studied leukemic cell DNA from 13 of the 17 cases of t(1;19)+ ALL, as well as cases lacking this translocation. Rearranged restriction fragments were detected in DNA from each of the tested cIg' leukemias containing the t (1;19) , as illustrated by the four representative cases shown in Fig 1. Interestingly, rearranged fragments were not detected in the three cases of early B-cell precursor leukemia with the t(1;19) whose patterns of normal E2A restriction fragments resembled those of leukemias without this translocation (Fig 1) .
Previous reports of analysis of cIg' leukemias suggest that the chromosomal breakpoints of the t(1;19) affect the same introns in every E2A-pbxl chimeric transcripts. 
IlThis karyotype is likely to represent residual normal marrow cells (see text). and 9.13
instance, resulting in expression of identical chimeric RNAs."'"~*" Therefore, we prepared oligonucleotides specific for sequences on each side of the breakpoint and used them to amplify cDNA templates synthesized from leukemic cell RNA (Fig 2A) . With a radiolabeled oligonucleotide probe specific for sequences spanning the E2A-pbxl junction, we detected transcripts in seven of eight cIg+ leukemias with the t(1;19) (lanes 2 through 8, Fig 2 8 and Table 1) . Surprisingly, E a -p b x l chimeric transcripts were not found in any of the five cIg-leukemias that had this translocation (lanes 21 through 25, Fig 2B) . These findings suggest that the breakpoints of the t(1;19) in cIg-cases do not result in expression of the same chimeric EM-pbxl transcripts detected in cIg' cases. Another exception is represented by patient 11 (Table l) , whose cIg' lymphoblasts had a t(1;19) but no detectable E2A-pbxl transcripts (lane 30, Fig 2B) .
E2A-pbxl expression was also detected in leukemic lymphoblasts from one of the eight patients with cIg' leukemia and no t(1;19) (patient 24, Fig 2B and Table 1 ). This child's leukemic cell karyotype differed from the others in that only normal chromosomes were identified in the 14 metaphases available for analysis (46,XX). It is likely that the karyotype in this case reflects only residual normal marrow cells, and that leukemic metaphases, presumably containing a t(1;19), were not identified because of low leukemic cell mitotic indices.
Because E2A-Pbxl fusion proteins are produced as a result of the t(1;19), and Pbxl proteins are not normally expressed in the early stages of B-cell differentiati~n,'~ we analyzed leukemic cells by immunoblot analysis with affinity-purified anti-Pbxl Igs. In 10 of the 11 cases of cIg' ALL with the t (1;19) , the blast cells expressed a characteristic array of E2A-Pbxl proteins, as Fig 3) , in which the leukemic cells had rearranged genomic E a , as detected by Southern blot analysis (data not shown), but lacked the fused E a -p b x l RNA (Fig 2B) . Although these proteins migrated closely with two of the five characteristic E2A-Pbxl chimeric proteins, their weak reactivity with anti-Pbxl Ig is also consistent with the possibility that they represent the products of a fusion between E2A and a PBXl -related gene. In addition to E2A-Pbxl proteins in cIg+, t(1;19)' cases, the affinity-purified rabbit anti-Pbxl antibodies stained approximately 20 polypeptides in all samples. Antibodies from a second rabbit that were also affinity-purified against recombinant Pbxl protein stained the same polypeptides, indicating that these cross-reactive polypeptides are either the products of PBXl-related genes or unrelated proteins that share antigenic determinants with Pbxl.
None of the five fusion proteins were present in the five cases of cIg-ALL with the t(1;19) (Fig 3) , consistent with PCR results showing an absence of EM-pbxl RNA ( Fig  2B) . The only cIg' leukemic cells lacking the t(1;19) that showed the typical set of five hybrid E2A-Pbxl proteins were those from patient 24, underscoring the close correlation between PCR and immunoblot assays in detecting these products.
cZg analysis. Cytoplasmic Ig p heavy chains were analyzed in each case by a sensitive immunofluorescence slide assay that distinguishes intracellular from plasma membrane expression of these molecules. Because molecular studies suggested that the cIg-cases did not have rearrangements of the E24 gene or express E2A-pbxl RNA or proteins, we further evaluated a subset of the cases for p . heavy chain expression by Western blot analysis. The results of Western blotting (Fig 4) agreed with those of the immunofluoresence slide assay, confirming that the expression of E2A-pbxl chimeric transcripts and proteins was restricted to t(1;19)' leukemias that express cIg.
DISCUSSION
Genetic alterations in developing B-lineage cells, affecting proteins involved in positive or negative regulation of cell growth and differentiation, can give rise to B-cell precursor ALL.*' In general, this subtype of leukemia responds well to chemotherapy and has a high likelihood of prolonged remission and One of several exceptions appears to be cIg' ALL with the t (1;19) , which has been related to a significantly worse clinical outcome than is usually seen in cIg' cases without this rearrangement or in most other subtypes of B-lineage ALL?' Results of a recent clinical trial suggest that the adverse prognostic impact of the t(1;19) in cIg' leukemias can be nullified with use of intensified chemotherapy?" Thus, accurate early detection of the t(1;19) in cases of cIg' ALL would be important in selecting appropriate treatment. Interestingly, the t(1;19) found in cIg-B-cell precursor leukemias appears to signify a standard risk of relapse on less intensive therapy (ref 6 and our unpublished observations, July 1991). This better prognosis may be related to the absence of E2A-pbxl transcripts and proteins, as opposed to those cases with a cIg' phenotype.
Expression of the EM-PBXI fusion gene, resulting from the 1;19 chromosomal translocation in cases of cIg' ALL, was reliably detected by molecular analysis demonstrating E2A gene rearrangements, chimeric E2A-pbxl transcripts, and hybrid E2A-Pbxl proteins in leukemic cells. These chimeric gene products were not found in cIg-cases that harbored the t ( 1;19) , even though the chromosomal breakpoints were indistinguishable by analysis of Giemsa-banded chromosomes. Our results suggest that neither the E2A nor the PBXI genes are altered by the translocations found in cIg-cases, indicating the need for analysis of other genes that might be affected by the t(1;19) chromosomal breakpoints in cIg-B-cell precursor ALL. Candidate genes located on the short arm of chromosome 19 include the LYL-I gene,26 which encodes a helix-loop-helix protein with similarities to E2A, and the VA Vcellular proto-oncogene."
The combination of molecular strategies used to identify characteristic E2A-PBXI rearrangements has several advantages. For example, the leukemic cells from patient 11 lacked E2A-pbxl RNAs in PCR assays, as well as the typical set of hybrid proteins found in other cases, despite evidence of rearrangements within the E2A gene by Southern blot analysis. Bands suggestive of two Pbx fusion proteins were identified by immunoblot analysis. Together, these results support two possible interpretations. First, this patient's leukemic cells may have contained an alternative junction between E2A and PBXI, resulting in a fusion transcript that excludes sequences recognized by the oligonucleotide primers used in the PCR assay. Such alternative breakpoints have been reported for BCR-ABL rearrangements in chronic myelogenous leukemia and Philadelphia chromosomepositive Alternatively, a PBX gene cluster may reside on chromosome 1, band q23, raising the possibility of fusions between EL1 and other PBX genes. We have sequenced a second gene contained in the PBXsubfamily of homeoboxes that is 88% identical to Pbxl at the amino acid level (M.P.K., unpublished observation, February 1991). At this point we have no strong evidence that favors either of these possibilities. Hunger et aI2' also observed a rare cIg' case that lacked chimeric E2A-pbxl transcripts, but they did not include analysis of hybrid proteins, so we cannot be certain if their patient was similar to ours (patient 11).
The E2A-Pbxl fusion proteins produced in cIg' B-cell precursors with typical t( 1;19) translocations are likely to play a critical role in pathogenesis. Previous studies have demonstrated conclusively that two of the five hybrid proteins (p85m-phx' and p77E2/\.Pha' ) result from alternatively spliced E2A-pbxl mRNAs, which encode different carboxyterminal amino acids.13 cDNA clones encoding these proteins were found to have different biologic activity when introduced into mouse fibroblasts: p77E2A.phx' but not P85E2/\.ha' induced large transformed foci in fibroblast together with the PCR products obtained after amplification using the indicated oligonucleotide pairs. A 164-bp fragment of the E2A-pbxl fusion transcript, spanning the junction site, was amplified with primers E5 and P3. A 180-bp fragment of the normal E2A transcript was also amplified as a control for RNA integrity, using the primers E5 and €3. The end-labeled oligonucleotide probes EP and E were used t o detect the chimeric and the normal transcripts in Southern blot analysis of RNA PCR products (E). The EZA-pbxl fragment was detected in RNA from t(l;l9)+ lymphoblasts that also express cytoplasmic Ig (lanes 2 through 8 monolayers, and p77E".Ph"l was more efficient in inducing both density-and anchorage-independent cell growth. Presumably, these proteins contribute to the transformation of Results of the present study, together with reports of high-risk leukemias with chimeric BCR-ABL fusion transcripts and protein^,'^.'^ suggest that systematic characterization of molecular defects within the broad category of B-cell precursor leukemias would provide sharper (and perhaps more prognostically relevant) distinctions than have immunologic approaches.
